LAEKNA-B (02105) announced its 2025 financial results, achieving revenue of approximately 107 million yuan and a gross profit of 86.419 million yuan. Research and development expenses reached about 250 million yuan, representing a year-on-year increase of 16.17%. The net loss narrowed to approximately 229 million yuan, a decrease of 9.82% compared to the previous year.

The company stated that the 2025 revenue was derived from an out-licensing agreement with Qilu Pharmaceutical for LAE002 (afuresertib). The rise in R&D expenses was primarily due to increased costs associated with the ActRII product portfolio, which includes LAE102, LAE103, and LAE123, as well as higher equity-settled share-based payment expenses.

As of December 31, 2025, the company had initiated seven clinical trials for LAE102, LAE103, LAE002 (afuresertib), LAE001, and LAE005, targeting unmet medical needs in the areas of obesity and cancer.